Skip to main content
. 2021 Mar 16;41(5):459–468. doi: 10.1007/s40261-021-01023-8

Table 3.

Cost-effectiveness analysis results

CAD or PAD PAD only CAD only
RIV + ASA ASA Δ RIV + ASA ASA Δ RIV + ASA ASA Δ
Cost category (€)
 Drug costs 9.391 200 9.191 9.047 188 8.859 9.379 200 9.180
 Direct health costs 9.252 12.659 − 3.407 14.418 18.962 − 4.544 8.538 11.395 − 2.857
 Total cost 18.643 12.858 5.785 23.465 19.150 4.315 17.917 11.594 6.323
Outcome
 QALYs, per patient 9.62 9.27 0.35 8.67 8.14 0.54 9.70 9.36 0.34
RIV + ASA vs. ASA RIV + ASA vs. ASA RIV + ASA vs. ASA
 ICER Incremental costs (€) Incremental effectiveness Incremental ratio (€) Incremental costs (€) Incremental effectiveness Incremental ratio (€) Incremental costs (€) Incremental effectiveness Incremental ratio (€)
 Cost per QALY 5.785 0.35 16.522 4.315 0.54 8.003 6.323 0.34 18.599
CAD and PAD CAD with CKD CAD with HF
RIV + ASA ASA Δ RIV + ASA ASA Δ RIV + ASA ASA Δ
Cost category (€)
 Drug costs 8.877 183 8.694 7.913 165 7.748 8.734 179 8.555
 Direct health costs 13.408 16.408 − 3.000 10.060 12.294 − 2.234 7.634 10.049 − 2.415
 Total cost 22.285 16.591 5.694 17.972 12.459 5.513 16.367 10.228 6.139
Outcome
 QALYs, per patient 8.63 8.07 0.56 7.76 7.34 0.43 8.70 8.08 0.62
RIV + ASA vs. ASA RIV + ASA vs. ASA RIV + ASA vs. ASA
 ICER Incremental costs (€) Incremental effectiveness Incremental ratio (€) Incremental costs (€) Incremental effectiveness Incremental ratio (€) Incremental costs (€) Incremental effectiveness Incremental ratio (€)
 Cost per QALY 5.694 0.56 10.199 5.513 0.43 12.971 6.139 0.62 9.905

All costs are reported in Euros (€)

Delta symbol defines the difference between information (costs, QALYs and ICERs) for RIV+ASA vs. ASA alone

CAD coronary artery disease, PAD peripheral artery disease, CKD chronic kidney disease, HF heart failure, RIV rivaroxaban, ASA aspirin, QALY quality-adjusted life-year, ICER incremental cost-effectiveness ratio

HHS Vulnerability Disclosure